Procarta raises €1.5 million to develop a new class of antibiotics to combat antimicrobial resistance | EU-Startups
Summary
Antimicrobial resistance (AMR) is a growing problem that threatens the effective prevention and treatment of an increasing range of infections caused by bacteria, parasites, viruses and fungi. The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) are responsible for a significant proportion of cUTIs and cIAIs throughout the world. CRE are often considered as the worst new “superbugs” as these bacteria can kill up to half of the patients who develop bloodstream infections from these pathogens. “The REPAIR investment comes in alongside investment from Procarta’s founding investor the UK Innovation & Science Seed Fund (UKI2S), as well as Wren Capital, Meltwind and Development Bank Wales,” said Dr Andrew Lightfoot, PhD, MBA, Chief Executive Officer of Procarta. “The money will be used to progress our lead asset, PRO-202 and to develop our proprietary drug discovery platform to build a pipeline of antimicrobial agents to cover the ESKAPE pathogens.